Microba Life Sciences Limited (MAP) Q2 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

morning everyone. I'm very pleased to share an update on our progress following close of the quarter ended 30 September 2024. This is our standard disclaimer. Now let me start by taking you through the strong numbers from the quarter. We delivered $3.65 million in revenue which is up 239% year-on-year and $5.07 million in cash receipts which is up 184% year-on-year. Importantly, we saw continued strong sales momentum for MetaExplore in Australia. Test sales up over 100% year-on-year, ordering clinicians up over 80% year-on-year, giving us an annualized run rate of over 7,300 tests and a strong start to Q2. With October, as at the end of last week, Friday the 25th, having already set a record sales month with a week left to go before we even finish the month. In the United Kingdom, we saw sustained growth in supplements up 3.6% year on year and relatively flat ordering clinician numbers year on year in line with the UK summer holiday period. And we weren't surprised to see testing sales down temporarily in Q1 with the UK summer holidays and our intentional focus on the team on preparations for meta explore access into the UK. And pleasingly, testing sales have already recovered as of the 25th of October with sales ahead of September. And aligned to that focus, the team have successfully launched an early access program for Meta Explore to key clinician accounts in October with first orders already flowing in. And aligned to this, we doubled the size of the sales force, setting up for growth and Meta Explore full access in the UK in 2025. Pleasingly, during October, our testing business is trading in line with expectations with both testing and supplement sales ahead of September back in line with non-summer holiday months. Now, Q1 traditionally is our soft quarter of ...